🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Steven Cohen’s ALLO Holdings & Trades

First Buy
Q3 2022
Duration Held
8 Quarters
Largest Add
Q4 2023
+679,468 Shares
Current Position
103,740 Shares
$142,124 Value

Steven Cohen's ALLO Position Overview

Steven Cohen (via Point72 Asset Management, L.P.) currently holds 103,740 shares of Allogene Therapeutics, Inc. (ALLO) worth $142,124, representing 0.00% of the portfolio. First purchased in 2022-Q3, this short-term holding has been held for 8 quarters.

Based on 13F filings, Steven Cohen has maintained this position in ALLO for several quarters, showing initial confidence in the investment. Largest addition occurred in Q4 2023, adding 679,468 shares. Largest reduction occurred in Q1 2024, reducing 679,468 shares.

Analysis based on 13F filings available since 2013 Q2

Steven Cohen's Allogene Therapeutics (ALLO) Holding Value Over Time

Track share changes against reported price movement

Quarterly Allogene Therapeutics (ALLO) Trades by Steven Cohen

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q4 2025 +103,740 New Buy 103,740 $1.37
Q1 2024 -679,468 Sold Out 0 $0.00
Q4 2023 +679,468 New Buy 679,468 $3.21
Q3 2023 -2,217 Sold Out 0 $0.00
Q2 2023 +119 Add 5.67% 2,217 $4.97
Q1 2023 +2,098 New Buy 2,098 $4.94
Q4 2022 -293,200 Sold Out 0 $0.00
Q3 2022 +293,200 New Buy 293,200 $10.80

Steven Cohen's Allogene Therapeutics Investment FAQs

Steven Cohen first purchased Allogene Therapeutics, Inc. (ALLO) in Q3 2022, acquiring 293,200 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Steven Cohen has held Allogene Therapeutics, Inc. (ALLO) for 8 quarters since Q3 2022.

Steven Cohen's largest addition to Allogene Therapeutics, Inc. (ALLO) was in Q4 2023, adding 679,468 shares worth $2.18 M.

According to the latest 13F filing for Q4 2025, Steven Cohen's firm, Point72 Asset Management, L.P., owns 103,740 shares of Allogene Therapeutics, Inc. (ALLO), valued at approximately $142,124.

As of the Q4 2025 filing, Allogene Therapeutics, Inc. (ALLO) represents approximately 0.00% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.

Steven Cohen's peak holding in Allogene Therapeutics, Inc. (ALLO) was 679,468 shares, as reported at the end of Q4 2023.